Back to top

5 Tech Stocks to Buy for Second Half of 2020 That Aren't FAANG or Microsoft

Read MoreHide Full Article

On today’s episode of Full Court Finance here at Zacks, Ben Rains takes a look at five tech stocks that investors might want to consider buying for the second half of 2020. Today we also made sure to focus on technology stocks that are not part of the FAANG group or named Microsoft (MSFT - Free Report) .

The Dow fell 3.3% last week as Wall Street assessed what to make of the continued spike in coronavirus cases in parts of the U.S. This has seen politicians in states such as California and Texas reverse some reopening plans. Meanwhile, Disney (DIS - Free Report) postponed the reopening of its California park and Apple (AAPL - Free Report) said it would shut down more stores in the Houston area.

Despite these setbacks, stocks surged Monday morning on the back of better-than-expected pending home sales. On top of that, investors might remain in don’t fight the Fed mode and stocks are still up big from their March lows. And let’s remember that the Nasdaq hit new high just last week on the back of gains from Apple, Amazon (AMZN - Free Report) , Microsoft, and others.

With this in mind, we looked at five stocks that are part of the broader technology sector that investors might want to consider buying for their ability to grow during the coronavirus economic uncertainty. These stocks also all provide longer-term growth potential within strong industries, including cloud computing.

Creative and business-focused software powerhouse Adobe (ADBE - Free Report) is the first stock up. We then dive into chip giant Nvidia (NVDA - Free Report) and stay-at-home standout Zoom Video (ZM - Free Report) . The episode then concludes with why Datadog (DDOG - Free Report) and Chegg (CHGG - Free Report) are both highly-ranked Zacks stocks at the moment.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Published in